Petros PharmaceuticalsPTPI +0.20% PB Ratio is 0.12 as of Jul. 01, 2026, which is 76% below its 10-year median of 0.50. Among 920 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 99.13% on this metric.
The historical rank and industry rank for Petros Pharmaceuticals's PB Ratio or its related term are showing as below:
PTPI'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.5 Max: 2.51
Current: 0.13
During the past 7 years, Petros Pharmaceuticals's highest PB Ratio was 2.51. The lowest was 0.01. And the median was 0.50.
PTPI's PB Ratio is ranked better than 99.13% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.89
vs PTPI: 0.13
During the past 3 years, the average Book Value Per Share Growth Rate was -93.00% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Petros Pharmaceuticals was -39.20% per year. The lowest was -93.00% per year. And the median was -66.10% per year.
Back to Basics: PB Ratio
Petros Pharmaceuticals (OTCPK:PTPI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Petros Pharmaceuticals (PTPI) has a PB Ratio of 0.12 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Petros Pharmaceuticals and its competitors. This is 76% below median its historical median of 0.50. Over the past decade, Petros Pharmaceuticals' PB Ratio has ranged from 0.01 to 2.51. According to the industry distribution chart, Petros Pharmaceuticals ranks #8 out of 920 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Petros Pharmaceuticals' PB Ratio too high?
Petros Pharmaceuticals' current PB Ratio of 0.12 is 76% below median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.51. The Drug Manufacturers industry median PB Ratio is 1.89. Petros Pharmaceuticals' value of 0.12 is 93.7% below this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #8 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' PB Ratio compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #8 out of 920 companies for PB Ratio. This places Petros Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.89. Petros Pharmaceuticals' value of 0.12 is 93.7% below this benchmark. Historically, Petros Pharmaceuticals' own PB Ratio has ranged from 0.01 to 2.51 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 1.89, Petros Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.89, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current PB Ratio of 0.12 is 93.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current PB Ratio is 0.12, which is 76% below median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current PB Ratio of 0.12. The current PB Ratio is 0.12, which is 76% below median its 10-year median of 0.50 and 93.7% below the Drug Manufacturers industry median of 1.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current PB Ratio is 0.12 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 